Feb 12 (Reuters) - Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a ...

GoodRx reports that the FDA has approved oral semaglutide (Wegovy) for weight loss, offering an alternative to injections ...

Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal ...

Patients wishing for an alternative to weight loss drug injections now have another option. The U.S. Food and Drug ...

Eli Lilly (LLY) stock is in focus as the company ramps up inventory for its weight loss pill orforglipron as its FDA approval nears in Q2 2026. Read more here.

Independent of FDA’s enhanced oversight, it’s clear that DTC promotion of weight loss drugs is having a moment, as companies go all in in pursuit of uptake expansion.

By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health on Thursday began offering a much ...

Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug ahead of an expected decision by the U.S. Food and Drug Administration in April, Reuters writes, ...

Dietary supplements are not approved for safety or efficacy by the U.S. Food and Drug Administration (FDA), and ingredients ...

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

By Stine Jacobsen and Maggie Fick COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk sued Hims and Hers Health on Monday over patent ...

Medications such as Wegovy and Zepbound will no longer be covered for weight loss, although GLP-1 drugs for diabetes will still be approved.